Welcome to our dedicated page for Nektar Therapeutics news (Ticker: NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics stock.
Nektar Therapeutics (Nasdaq: NKTR) generates a steady flow of news tied to its role as a clinical-stage biotechnology company focused on autoimmune and chronic inflammatory diseases. Company announcements emphasize progress with its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), a regulatory T cell stimulator and IL-2 pathway agonist being evaluated in multiple mid-stage trials.
News coverage frequently highlights clinical data from the REZOLVE-AD Phase 2b study in moderate-to-severe atopic dermatitis and the REZOLVE-AA Phase 2b study in severe-to-very-severe alopecia areata. Press releases describe topline results, detailed efficacy and safety outcomes, and analyses in subgroups such as patients with atopic dermatitis and a history of asthma, including Asthma Control Questionnaire (ACQ-5) findings.
Investors and observers can also find updates on regulatory interactions, such as the U.S. Food and Drug Administration granting Fast Track designations for rezpegaldesleukin in atopic dermatitis and alopecia areata. Additional news items cover Nektar’s participation in scientific and investor conferences, late-breaking oral presentations at major dermatology and allergy meetings, and corporate events like equity offerings and compliance updates related to its Nasdaq Capital Market listing.
This news page aggregates these disclosures so readers can follow developments in Nektar’s immunology pipeline, including rezpegaldesleukin and other programs such as NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255. For those tracking NKTR stock or the evolution of Treg-focused therapies, this feed provides a centralized view of clinical milestones, financial communications and key corporate announcements.
Nektar Therapeutics (Nasdaq: NKTR) reported third-quarter 2025 results for the period ended September 30, 2025. Cash and marketable securities were $270.2M (includes July secondary offering net proceeds and ATM proceeds); company expects cash to support operations into Q2 2027. Revenue was $11.8M in Q3 2025 versus $24.1M in Q3 2024, reflecting the December 2024 sale of the Huntsville manufacturing facility. R&D expense was $27.3M in Q3; Net loss was $35.5M ($1.87 per share) in Q3 and $128.0M year-to-date.
Key clinical and corporate items: REZOLVE-AD data presented at EADV and ACAAI; FDA granted Fast Track for rezpegaldesleukin in severe-to-very-severe alopecia areata; company raised capital including a $115M gross public offering and ATM proceeds.
Nektar Therapeutics (Nasdaq: NKTR) announced that company management will present at the Jefferies Global Healthcare Conference in London, held November 17-20, 2025.
The company will host a fireside chat on Thursday, November 20, 2025, webcast live at 11:00 a.m. GMT / 3:00 a.m. PT. The webcast is accessible via the company’s Investor Events webpage and a replay will be available for 30 days. Investors seeking one-on-one meetings should contact their Jefferies representative.
Nektar (Nasdaq:NKTR) will announce its third-quarter 2025 financial results on Thursday, November 6, 2025 after the U.S. market close. Howard Robin, President and CEO, will host a conference call at 5:00 p.m. ET / 2:00 p.m. PT to review results. A press release and an audio-only webcast link will be posted on the company's investor relations site at https://ir.nektar.com/. The web broadcast replay will be available through December 6, 2025. Investors must pre-register to receive dial-in details and a PIN to access the live call.
Nektar Therapeutics (Nasdaq:NKTR) announced that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and Treg proliferator, was accepted for a late-breaking oral abstract presentation at the ACAAI 2025 Annual Scientific Meeting.
The oral presentation (Abstract ID: 7005) titled "Rezpegaldesleukin Novel Treg-Inducing Therapy Demonstrates Efficacy in Atopic Dermatitis and Asthma in Phase 2b Trial" will be delivered by Jonathan Corren, MD on Saturday, November 8, 2025 at 5:33 PM ET in Room W231. The meeting runs November 6–10, 2025 in Orlando, and the presentation will be posted on Nektar's Scientific Publications page after the formal presentation.
Nektar Therapeutics (Nasdaq: NKTR) announced positive results from its REZOLVE-AD Phase 2b study of rezpegaldesleukin for moderate-to-severe atopic dermatitis at the EADV Congress. The study met its primary endpoint with significant mean improvement in EASI scores at week 16 across all treatment arms versus placebo.
The high dose (24 µg/kg q2w) demonstrated strong efficacy with 61% mean EASI improvement, 42% EASI-75 response, and 20% vIGA-AD 0/1 response. Notably, patients who crossed over from placebo showed deepening responses after 24 weeks, with EASI-75 reaching 62% and vIGA-AD 0/1 reaching 38%.
The drug showed a favorable safety profile with 60.3% treatment-emergent adverse events across treatment arms, comparable to placebo's 57.5%, and only 1.6% serious adverse events.
Nektar Therapeutics (NASDAQ:NKTR) has announced that results from its REZOLVE-AD Phase 2b study for rezpegaldesleukin in atopic dermatitis will be presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris.
The presentation will cover primary and secondary endpoints from the 16-week induction phase, including multiple patient-reported outcomes. Additionally, new data will be presented from placebo patients who crossed over to high-dose rezpegaldesleukin treatment. Dr. Jonathan Silverberg will deliver the late-breaker oral presentation on September 18th at 14:45.
Nektar Therapeutics (NASDAQ:NKTR) announced its participation in two upcoming investor conferences in September 2025. The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10 at 10:30 AM ET in New York City, and the Stifel Virtual Immunology and Inflammation Forum on September 15 at 2:30 PM ET.
Both presentations will be available via webcast through the company's investor relations website, with replays accessible for 30 days. Investors interested in one-on-one meetings with management can arrange them through their representatives.
Nektar Therapeutics (Nasdaq: NKTR) reported Q2 2025 financial results, with cash and investments of $175.9 million as of June 30, 2025, down from $269.1 million in December 2024. The company raised additional $107.5 million through a secondary offering in July 2025, extending operations into Q1 2027.
Key financial metrics include Q2 2025 revenue of $11.2 million (down from $23.5 million in Q2 2024) and a net loss of $41.6 million ($2.95 per share). The company reported significant progress with rezpegaldesleukin in Phase 2b studies for atopic dermatitis, achieving statistical significance in primary and secondary endpoints. The FDA granted Fast Track designation for rezpegaldesleukin in alopecia areata treatment.
Nektar Therapeutics (NASDAQ:NKTR) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, after U.S. market close. The company will host a conference call at 5:00 p.m. ET/2:00 p.m. PT, led by President and CEO Howard Robin.
Investors can access the audio-only webcast through the company's investor relations website at ir.nektar.com. The webcast replay will remain available until September 7, 2025. Participants wishing to join via phone must pre-register through the Nektar Earnings Call Registration link to receive dial-in information.
Nektar Therapeutics (NASDAQ:NKTR) has received Fast Track designation from the FDA for rezpegaldesleukin, targeting severe-to-very severe alopecia areata treatment in adults and children 12+ years weighing at least 40kg.
Rezpegaldesleukin is an investigational biologic therapy targeting the interleukin-2 receptor complex to stimulate regulatory T cells (Tregs) proliferation. The company expects to announce topline data from the REZOLVE-AA Phase 2b study in December 2025.
The Fast Track designation enables more frequent FDA interactions and potential eligibility for rolling and priority review, aiming to accelerate the development of treatments addressing unmet medical needs.